Clinical trials: Neoplasms, Metastatic
Metastatic Hormone-sensitive Prostate Cancer
A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.
The purpose of the study is to assess if the addition of darolutamide to ADT compared with ADT alone would result in superior clinical efficacy in participants with metastatic hormone-sensitive prostate cancer (mHSPC) by…
- Trial name
- ARASEC (NCT05059236)
- Testing
- Darolutamide (BAY1841788, Nubeqa), ADT
- Where
- 31 sites in United States
- Volunteers
- 223 people
- Sponsor
- Bayer
Non Small Cell Lung Cancer, EGFR Gene Mutation
Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
The primary objective of the study is to evaluate the efficacy of osimertinib plus ramucirumab versus osimertinib alone using progression free survival (PFS).
- Conditions
- Non Small Cell Lung Cancer, EGFR Gene Mutation, Advanced Cancer, Metastatic Cancer
- Trial name
- NCT03909334
- Testing
- Osimertinib, Ramucirumab
- Where
- 12 sites in United States
- Volunteers
- 160 people
- Sponsor
- Xiuning Le
Metastatic Neuroblastoma
A Phase I/II Study of [124I]mIBG PET/CT in Neuroblastoma
This study aims to show that 3-dimensional PET/CT imaging with a new novel PET tracer (called [124I]mIBG) can detect as many or more sites of neuroblastoma (a type of childhood cancer) compared to the recommended 1-dimensional…
- Trial name
- NCT02043899
- Testing
- [124I]meta-Iodobenzylguanidine
- Where
- 2 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- Cancer Research UK
Recurrent Melanoma, Stage IV Melanoma
Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations
This phase II trial studies intermittent dosing of BRAF inhibitor LGX818 (encorafenib) and MEK inhibitor MEK 162 (binimetinib) in treating patients with melanoma that has spread to other parts of the body (metastatic) and have a…
- Trial name
- NCT02263898
- Testing
- Raf kinase inhibitor LGX818, binimetinib, laboratory biomarker analysis
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Biliary Tract Cancer
Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer
1. Goals The primary goal of this phase II trial is to: evaluate the response rate of combination chemotherapy with Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan in patients with locally advanced or metastatic Biliary…
- Trial name
- NCT01494363
- Testing
- Fluorouracil, Leucovorin, Oxaliplatin
- Where
- 3 sites in South Korea
- Volunteers
- 53 people
- Sponsor
- Soon Chun Hyang University
Solid Tumors
MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors
The main purpose of this study was to assess the safety and tolerability of MSB0011359C. Study consists of dose-escalation part and an expansion part in participants with metastatic or locally advanced solid tumors, for which no…
- Trial name
- NCT02699515
- Testing
- MSB0011359C
- Where
- 18 sites in Japan, South Korea and 1 more
- Volunteers
- 114 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Non Small Cell Lung Cancer
MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer
This study will compare the rate of chemotherapy: pemetrexed and cisplatin compared with the combination of pemetrexed/cisplatin with MK-0646.
- Trial name
- IMPACT (NCT00799240)
- Testing
- Arm A: Pemetrexed Cisplatin, Arm B Pemetrexed, Cisplatin and MK-0646
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- University of Kansas
Metastatic Melanoma
Radiation and Combination Immunotherapy for Melanoma
This is a Phase 2 study designed to evaluate the combination of checkpoint blockade and aldesleukin (IL-2) therapy after a course of standard of care palliative radiation in the management of unresectable metastatic melanoma.
- Trial name
- NCT03850691
- Testing
- Aldesleukin: All Patients, Nivolumab: Cohort 1 (Cutaneous), Nivolumab: Cohort 2 (Ocular)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Breast Cancer
Ixabepilone in Treating Patients With Locally Advanced or Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well ixabepilone works in treating patients with locally…
- Trial name
- NCT00045097
- Testing
- ixabepilone
- Where
- 4 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer, Adjuvant Chemotherapy
A Trial Comparing Adjuvant Chemotherapy With Observation After Concurrent Chemoradiotherapy of Cervical Cancer (With Pelvic or Para-aortic Node Involvement)
Cervical cancer with pelvic or para-aortic node involvement has a poor prognosis. Despite low-quality data, the routine practice to treat these patients is radiation with concurrent cisplatin.
- Conditions
- Cervical Cancer, Adjuvant Chemotherapy, Radiation, Lymph Node Metastases
- Trial name
- NCT03468010
- Testing
- chemoradiation, Paclitaxel, Cisplatin
- Where
- 8 sites in China
- Volunteers
- 432 people
- Sponsor
- Sun Yat-sen University
Metastatic Colorectal Cancer, Drug Therapy
Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC
To evaluate the efficacy and safety of trifluridine/tipiracil combined with fufuquitinib versus trifluridine/tipiracil and fufuquitinib in patients with unresectable metastatic colorectal cancer.
- Trial name
- NCT06485713
- Testing
- trifluridine/tipiracil combined with fufuquitinib, fufuquitinib, Trifluridine/tipiracil
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Melanoma Stage Iv, Metastatic Melanoma
Metastatic Melanoma Patients on Immunotherapy With Nutritive Intervention Based on Mediterranean Diet
This research will study the effect of Mediterranean diet intervention in patients undergoing immunotherapy treatment for metastatic melanoma and its relationship with gut microbiome and quality of life.
- Trial name
- MINI-MD (NCT06236360)
- Testing
- Mediterranean Diet Intervention
- Where
- Croatia
- Volunteers
- 30 people
- Sponsor
- University Hospital Rijeka
Breast Cancer
Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients
The purpose of this trial is to test the safety of a vaccine made from a patient's own breast cancer cells, and determine if this vaccine will delay or stop the growth of the cancer.
- Trial name
- NCT00317603
- Testing
- Autologous, Lethally Irradiated Breast Cancer Cells
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Dana-Farber Cancer Institute
Cancer Pain
Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain
This is a Phase Ib/IIa, multicenter, sequential clinical trial evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of SSS40 injection in patients with moderate-to-severe bone metastatic cancer…
- Trial name
- NCT07008703
- Testing
- Injection of humanized nerve growth factor (NGF) antibody
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Treatment Efficacy
Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer
A number of anti-PD-1/L1 monoclonal antibodies have been approved for the treatment of various advanced tumors in the world, and many studies on anti-PD-1 /L1 monoclonal antibodies for breast cancer are also being carried out.
- Trial name
- CHANGEABLE (NCT04508803)
- Testing
- HX008，Niraparib, HX008，Niraparib，Trastuzumab, HX008，Niraparib，Pyrrolitinib
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Fudan University
Non-Small Cell Lung Cancer, Triple-negative Breast Cancer
Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC
Part 1of the study will evaluate the safety, pharmacokinetics, pharmacodynamics and immunogenicity of increasing doses of a vaccine-based immunotherapy regimen (VBIR-2) for patients with advanced or metastatic non-small cell lung…
- Trial name
- NCT03674827
- Testing
- PF-06936308
- Where
- 34 sites in United States
- Volunteers
- 36 people
- Sponsor
- Pfizer
Breast Cancer
Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT00722072
- Testing
- fulvestrant, sorafenib tosylate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- OHSU Knight Cancer Institute
Colorectal Neoplasms Malignant
TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)
Liver metastases are a leading cause of death among patients with metastatic colorectal cancer. Duration of disease control is short following 2nd-line or later systemic therapy.
- Trial name
- TACE-Ax-HCQ (NCT04873895)
- Testing
- Axitinib 5 MG, Hydroxychloroquine Pill, trans arterial chemoembolization
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Gastric Cancer, Peritoneal Metastases
Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
Peritoneal metastasis of gastric cancer is difficult to be detected in time, thus delaying treatment. Based on the conventional CT images of gastric cancer, this study plans to develop, improve and validate an intelligent…
- Trial name
- NCT05722275
- Testing
- Peritoneal metastasis status ascertainment
- Where
- 13 sites in China, Italy
- Volunteers
- 400 people
- Sponsor
- Chinese Academy of Sciences
Solid Tumors
Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors
Primary Objective: To determine the maximum tolerated dose(s) (MTD) and the recommended Phase 2 dose(s) (RP2D) of SAR245408 and MSC1936369B when combined in adult subjects with locally advanced or metastatic solid tumors.
- Trial name
- NCT01357330
- Testing
- SAR245408 (XL147), MSC1936369B
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.